Rhumbline Advisers Acquires 23,564 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rhumbline Advisers grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 7.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,032 shares of the company’s stock after purchasing an additional 23,564 shares during the period. Rhumbline Advisers’ holdings in Recursion Pharmaceuticals were worth $2,258,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Axxcess Wealth Management LLC increased its stake in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after buying an additional 1,795 shares during the last quarter. Wedmont Private Capital lifted its holdings in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after purchasing an additional 2,000 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after acquiring an additional 2,346 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Recursion Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock valued at $346,000 after acquiring an additional 2,667 shares during the period. Finally, KBC Group NV lifted its position in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $6.59 on Tuesday. The firm has a market cap of $2.57 billion, a PE ratio of -4.31 and a beta of 0.86. The company’s fifty day simple moving average is $7.71 and its two-hundred day simple moving average is $7.09. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $12.93.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue was down 57.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.42) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RXRX. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.